Free Trial

Blueprint Medicines (BPMC) Stock Forecast & Price Target

$105.21
-1.50 (-1.41%)
(As of 06/20/2024 ET)

Blueprint Medicines - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$108.00
2.65% Upside
High Forecast$168.00
Average Forecast$108.00
Low Forecast$63.00
TypeCurrent Forecast
6/22/23 to 6/21/24
1 Month Ago
5/23/23 to 5/22/24
3 Months Ago
3/24/23 to 3/23/24
1 Year Ago
6/22/22 to 6/22/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$108.00$102.65$85.43$75.67
Forecasted Upside2.65% Upside11.88% Upside14.43% Upside43.08% Upside
Get Blueprint Medicines Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

BPMC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BPMC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Blueprint Medicines Stock vs. The Competition

TypeBlueprint MedicinesMedical CompaniesS&P 500
Consensus Rating Score
2.63
2.70
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside2.65% Upside1,099.77% Upside11.13% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/7/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$125.00 ➝ $125.00+19.90%
5/14/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Loganathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$140.00+29.57%
5/6/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
5/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$121.00 ➝ $168.00+57.78%
5/6/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform$50.00 ➝ $97.00-9.51%
5/3/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$65.00 ➝ $76.00-29.10%
5/3/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$125.00 ➝ $135.00+25.94%
5/3/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$70.00 ➝ $75.00-30.70%
5/3/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$78.00 ➝ $104.00-5.98%
5/2/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$97.00 ➝ $97.00+2.26%
4/26/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$120.00 ➝ $130.00+40.00%
4/26/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$110.00 ➝ $110.00+17.51%
12/22/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetStrong-Buy ➝ Strong-Buy$85.00 ➝ $100.00+16.37%
12/19/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$86.00 ➝ $115.00+31.26%
10/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$59.00 ➝ $63.00+14.09%
10/27/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$85.00+53.93%
6/5/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform ➝ Underperform$48.00 ➝ $43.00-26.14%
5/23/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$78.00 ➝ $82.00+45.78%
5/5/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
11/2/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Eun Yang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$84.00 ➝ $80.00+65.84%
9/14/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.00+27.23%
9/7/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$80.00 ➝ $90.00+27.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:10 AM ET.

BPMC Forecast - Frequently Asked Questions

What is Blueprint Medicines's stock forecast and purchase recommendation?

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Blueprint Medicines is $108.00, with a high forecast of $168.00 and a low forecast of $63.00. The consensus rating for Blueprint Medicines stock is Moderate Buy based on the current 1 sell rating, 5 hold ratings, 9 buy ratings and 1 strong buy rating for BPMC. Learn more on BPMC's analyst rating history.

Do Wall Street analysts like Blueprint Medicines more than its competitors?

Analysts like Blueprint Medicines less than other "medical" companies. The consensus rating score for Blueprint Medicines is 2.63 while the average consensus rating score for "medical" companies is 2.70. Learn more on how BPMC compares to other companies.

Is Blueprint Medicines being upgraded by Wall Street analysts?

Over the previous 90 days, Blueprint Medicines's stock had 2 upgrades by analysts.

Does Blueprint Medicines's stock price have much upside?

According to analysts, Blueprint Medicines's stock has a predicted upside of 13.72% based on their 12-month stock forecasts.

What analysts cover Blueprint Medicines?

Blueprint Medicines has been rated by research analysts at Barclays, Citigroup, HC Wainwright, JMP Securities, Leerink Partnrs, Needham & Company LLC, Piper Sandler, Stephens, Stifel Nicolaus, SVB Leerink, The Goldman Sachs Group, and Wedbush in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:BPMC) was last updated on 6/21/2024 by MarketBeat.com Staff

From Our Partners